PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 12, 2015, Pages 2517-2525

  Demers, Annie ^a   Samami, Samaneh ^a,d   Lauzier, Benjamin ^b   Des Rosiers, Christine ^a,e   Sock, Emilienne Tudor Ngo ^a,d   Ong, Huy ^c   Mayer, Gaetan ^a,d  

^a MONTREAL HEART INSTITUTE   (Canada)

^b UNIVERSITÉ DE NANTES   (France)

^c Faculty of Pharmacy   (France)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e Faculty of Medicine   (Canada)

Author keywords

Antigens; CD36; knockout; LDL; mice; mouse; Pcsk9 protein; receptors; triglyceride

Indexed keywords

CD36 ANTIGEN; FAT DROPLET; LONG CHAIN FATTY ACID; OXIDIZED LOW DENSITY LIPOPROTEIN; PALMITIC ACID DERIVATIVE; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; SMALL INTERFERING RNA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 4,4-DIFLUORO-5,7-DIMETHYL-4-BORA-3A,4A-DIAZA-S-INDACENE-3-HEXADECANOIC ACID; BORON DERIVATIVE; FATTY ACID; LOW DENSITY LIPOPROTEIN; PCSK9 PROTEIN, HUMAN; PCSK9 PROTEIN, MOUSE; PROTEASOME; PROTEASOME INHIBITOR;

ADIPOCYTE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; EMBRYO; ENDOPLASMIC RETICULUM; FATTY ACID TRANSPORT; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; INTRAABDOMINAL FAT; LIPID METABOLISM; LIPID STORAGE; LIVER; LYSOSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SURFACE PLASMON RESONANCE; 3T3 CELL LINE; ANIMAL; C57BL MOUSE; DEFICIENCY; DRUG EFFECTS; ENZYMOLOGY; FEMALE; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; KNOCKOUT MOUSE; MALE; METABOLISM; RNA INTERFERENCE; TIME;

3T3-L1 CELLS; ADIPOCYTES; ANIMALS; ANTIGENS, CD36; BORON COMPOUNDS; FATTY ACIDS; FEMALE; HEK293 CELLS; HEP G2 CELLS; HUMANS; INTRA-ABDOMINAL FAT; LIPOPROTEINS, LDL; LIVER; LYSOSOMES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PALMITIC ACIDS; PROPROTEIN CONVERTASES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PROTEOLYSIS; RNA INTERFERENCE; SERINE ENDOPEPTIDASES; TIME FACTORS; TRANSFECTION; TRIGLYCERIDES;

EID: 84948120794     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.115.306032     Document Type: Article

References (44)

1. Do R, Stitziel NO, Won HH, et al; NHLBI Exome Sequencing Project. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature. 2015;518:102-106. doi: 10.1038/nature13917.
2. Kotowski IK, Pertsemlidis A, Luke A, Cooper RS, Vega GL, Cohen JC, Hobbs HH. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet. 2006;78:410-422. doi: 10.1086/500615.
3. Maxwell KN, Fisher EA, Breslow JL. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci USA. 2005;102:2069-2074. doi: 10.1073/pnas.0409736102.
4. Abifadel M, Varret M, Rabès JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154-156. doi: 10.1038/ng1161.
5. Timms KM, Wagner S, Samuels ME, Forbey K, Goldfine H, Jammulapati S, Skolnick MH, Hopkins PN, Hunt SC, Shattuck DM. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet. 2004;114:349-353. doi: 10.1007/s00439-003-1071-9.
6. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264-1272. doi: 10.1056/NEJMoa054013.
7. Poirier S, Mayer G. The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. Drug Des Devel Ther. 2013;7:1135-1148. doi: 10.2147/DDDT.S36984.
8. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, Basak A, Prat A, Chretien M. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA. 2003;100:928-933. doi: 10.1073/pnas.0335507100.
9. Mayer G, Poirier S, Seidah NG. Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels. J Biol Chem. 2008;283:31791-31801. doi: 10.1074/jbc. M805971200.
10. Mayer G, Hamelin J, Asselin MC, Pasquato A, Marcinkiewicz E, Tang M, Tabibzadeh S, Seidah NG. The regulated cell surface zymogen activation of the proprotein convertase PC5A directs the processing of its secretory substrates. J Biol Chem. 2008;283:2373-2384. doi: 10.1074/jbc. M708763200.
11. Cunningham D, Danley DE, Geoghegan KF, et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol. 2007;14:413-419. doi: 10.1038/nsmb1235.
12. McNutt MC, Lagace TA, Horton JD. Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J Biol Chem. 2007;282:20799-20803. doi: 10.1074/jbc. C700095200.
13. Zhang DW, Lagace TA, Garuti R, Zhao Z, McDonald M, Horton JD, Cohen JC, Hobbs HH. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem. 2007;282:18602-18612. doi: 10.1074/jbc.M702027200.
14. Poirier S, Mayer G, Benjannet S, Bergeron E, Marcinkiewicz J, Nassoury N, Mayer H, Nimpf J, Prat A, Seidah NG. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem. 2008;283:2363-2372. doi: 10.1074/jbc.M708098200.
15. Labonté P, Begley S, Guévin C, Asselin MC, Nassoury N, Mayer G, Prat A, Seidah NG. PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression. Hepatology. 2009;50:17-24. doi: 10.1002/hep.22911.
16. Sharotri V, Collier DM, Olson DR, Zhou R, Snyder PM. Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9 (PCSK9). J Biol Chem. 2012;287:19266-19274. doi: 10.1074/jbc.M112.363382.
17. Jonas MC, Costantini C, Puglielli L. PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1. EMBO Rep. 2008;9:916-922. doi: 10.1038/embor.2008.132.
18. Lakoski SG, Lagace TA, Cohen JC, Horton JD, Hobbs HH. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab. 2009;94:2537-2543. doi: 10.1210/jc.2009-0141.
19. Le May C, Kourimate S, Langhi C, Chétiveaux M, Jarry A, Comera C, Collet X, Kuipers F, Krempf M, Cariou B, Costet P. Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. Arterioscler Thromb Vasc Biol. 2009;29:684-690. doi: 10.1161/ATVBAHA.108.181586.
20. Silverstein RL, Febbraio M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal. 2009;2:re3. doi: 10.1126/scisignal.272re3.
21. Koonen DP, Jacobs RL, Febbraio M, Young ME, Soltys CL, Ong H, Vance DE, Dyck JR. Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity. Diabetes. 2007;56:2863-2871. doi: 10.2337/db07-0907.
22. Rashid S, Curtis DE, Garuti R, Anderson NN, Bashmakov Y, Ho YK, Hammer RE, Moon YA, Horton JD. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci USA. 2005;102:5374-5379. doi: 10.1073/pnas.0501652102.
23. Bolduc OR, Lambert-Lanteigne P, Colin DY, Zhao SS, Proulx C, Boeglin D, Lubell WD, Pelletier JN, Féthière J, Ong H, Masson JF. Modified peptide monolayer binding His-tagged biomolecules for small ligand screening with SPR biosensors. Analyst. 2011;136:3142-3148. doi: 10.1039/c1an15235a.
24. Shan L, Pang L, Zhang R, Murgolo NJ, Lan H, Hedrick JA. PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide. Biochem Biophys Res Commun. 2008;375:69-73. doi: 10.1016/j. bbrc.2008.07.106.
25. Fisher TS, Lo Surdo P, Pandit S, et al. Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation. J Biol Chem. 2007;282:20502-20512. doi: 10.1074/jbc.M701634200.
26. Kwon HJ, Lagace TA, McNutt MC, Horton JD, Deisenhofer J. Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci USA. 2008;105:1820-1825. doi: 10.1073/pnas.0712064105.
27. Tran TT, Poirier H, Clément L, Nassir F, Pelsers MM, Petit V, Degrace P, Monnot MC, Glatz JF, Abumrad NA, Besnard P, Niot I. Luminal lipid regulates CD36 levels and downstream signaling to stimulate chylomicron synthesis. J Biol Chem. 2011;286:25201-25210. doi: 10.1074/jbc. M111.233551.
28. Luiken JJ, Dyck DJ, Han XX, Tandon NN, Arumugam Y, Glatz JF, Bonen A. Insulin induces the translocation of the fatty acid transporter FAT/CD36 to the plasma membrane. Am J Physiol Endocrinol Metab. 2002;282:E491-E495. doi: 10.1152/ajpendo.00419.2001.
29. Longva KE, Blystad FD, Stang E, Larsen AM, Johannessen LE, Madshus IH. Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies. J Cell Biol. 2002;156:843-854. doi: 10.1083/jcb.200106056.
30. Grefhorst A, McNutt MC, Lagace TA, Horton JD. Plasma PCSK9 preferentially reduces liver LDL receptors in mice. J Lipid Res. 2008;49:1303-1311. doi: 10.1194/jlr.M800027-JLR200.
31. Matter K, Hunziker W, Mellman I. Basolateral sorting of LDL receptor in MDCK cells: the cytoplasmic domain contains two tyrosine-dependent targeting determinants. Cell. 1992;71:741-753.
32. Wang Y, Huang Y, Hobbs HH, Cohen JC. Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR. J Lipid Res. 2012;53:1932-1943. doi: 10.1194/jlr.M028563.
33. Korolchuk VI, Menzies FM, Rubinsztein DC. Mechanisms of cross-talk between the ubiquitin-proteasome and autophagy-lysosome systems. FEBS Lett. 2010;584:1393-1398. doi: 10.1016/j.febslet.2009.12.047.
34. Miranda M, Sorkin A. Regulation of receptors and transporters by ubiquitination: new insights into surprisingly similar mechanisms. Mol Interv. 2007;7:157-167. doi: 10.1124/mi.7.3.7.
35. Smith J, Su X, El-Maghrabi R, Stahl PD, Abumrad NA. Opposite regulation of CD36 ubiquitination by fatty acids and insulin: effects on fatty acid uptake. J Biol Chem. 2008;283:13578-13585. doi: 10.1074/jbc.M800008200.
36. Seidah NG, Poirier S, Denis M, Parker R, Miao B, Mapelli C, Prat A, Wassef H, Davignon J, Hajjar KA, Mayer G. Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation. PLoS One. 2012;7:e41865. doi: 10.1371/journal.pone.0041865.
37. Nguyen MA, Kosenko T, Lagace TA. Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts. J Lipid Res. 2014;55:266-275. doi: 10.1194/jlr.M044156.
38. Heit B, Kim H, Cosió G, Castanõ D, Collins R, Lowell CA, Kain KC, Trimble WS, Grinstein S. Multimolecular signaling complexes enable Syk-mediated signaling of CD36 internalization. Dev Cell. 2013;24:372-383. doi: 10.1016/j.devcel.2013.01.007.
39. Levy E, Ben Djoudi Ouadda A, Spahis S, Sane AT, Garofalo C, Grenier É, Emonnot L, Yara S, Couture P, Beaulieu JF, Ménard D, Seidah NG, Elchebly M. PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells. Atherosclerosis. 2013;227:297-306. doi: 10.1016/j.atherosclerosis.2013.01.023.
40. Roubtsova A, Munkonda MN, Awan Z, Marcinkiewicz J, Chamberland A, Lazure C, Cianflone K, Seidah NG, Prat A. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler Thromb Vasc Biol. 2011;31:785-791. doi: 10.1161/ATVBAHA.110.220988.
41. Febbraio M, Abumrad NA, Hajjar DP, Sharma K, Cheng W, Pearce SF, Silverstein RL. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J Biol Chem. 1999;274:19055-19062.
42. Tavori H, Fan D, Blakemore JL, Yancey PG, Ding L, Linton MF, Fazio S. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation. Circulation. 2013;127:2403-2413. doi: 10.1161/CIRCULATIONAHA.113.001592.
43. Sheedfar F, Sung MM, Aparicio-Vergara M, Kloosterhuis NJ, Miquilena-Colina ME, Vargas-Castrillón J, Febbraio M, Jacobs RL, de Bruin A, Vinciguerra M, Garciá-Monzón C, Hofker MH, Dyck JR, Koonen DP. Increased hepatic CD36 expression with age is associated with enhanced susceptibility to nonalcoholic fatty liver disease. Aging (Albany NY). 2014;6:281-295.
44. Cariou B, Le May C, Costet P. Clinical aspects of PCSK9. Atherosclerosis. 2011;216:258-265. doi: 10.1016/j.atherosclerosis.2011.04.018.